Clinical trial · no report yet · Phase 2
NCT02254785
Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer
- NCT02254785 ↗
- Unknown
- British Columbia Cancer Agency
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| Bluesky threads | 2 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase II, Randomized, Multi-center Study of Cabazitaxel Versus Abiraterone or Enzalutamide in Poor Prognosis-metastatic Castration-resistant Prostate Cancer
- Phase
- Phase 2
- Status
- Unknown
- Conditions
- Metastatic Castration-Resistant Prostatic Cancer
- Interventions
- cabazitaxel; Abiraterone; Enzalutamide 160mg daily (oral)
- Arms
- Cabazitaxel · Experimental
- Abiraterone or enzalutamide · Active comparator
- Enrollment
- 120 (estimated)
- Primary outcomes
- Clinical benefit rate
- Sponsor
- British Columbia Cancer Agency with Sanofi, Ozmosis Research Inc.
- Start
- Oct 2014
- Primary completion
- May 2020 (estimated)
- Results posted
- No
- Registry record
- NCT02254785 · updated Dec 6, 2017
Publications
linked from the registry- Annala M, Fu S, Bacon JVW, Sipola J, Iqbal N, Ferrario C, Ong M, Wadhwa D, Hotte SJ, Lo G, Tran B, Wood LA, Gingerich JR, North SA, Pezaro CJ, Ruether JD, Sridhar SS, Kallio HML, Khalaf DJ, Wong A, Beja K, Schonlau E, Taavitsainen S, Nykter M, Vandekerkhove G, Azad AA, Wyatt AW, Chi KN. Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial. Ann Oncol. 2021 Jul;32(7):896-905. doi: 10.1016/j.annonc.2021.03.205. Epub 2021 Apr 6. PubMed 33836265